Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Overview: PerkinElmer is a leading provider of scientific instruments, consumables, and services to pharmaceutical, biomedical, academic research, environmental testing, and industrial markets. The company operates through two reporting segments: Life and Analytical Sciences (drug discovery, genetic screening, environmental analysis) and Optoelectronics (digital imaging, sensors, specialty lighting). The company divested its Fluid Sciences segment in 2005 and 2006, reporting those results as discontinued operations.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Sales (Continuing Operations) | $1,546.4 million | $1,473.8 million |
| Operating Income (Continuing Operations) | $153.4 million | $141.0 million |
| Net Income | $119.6 million | $268.1 million |
| Diluted EPS (Net Income) | $0.95 | $2.04 |
| Gross Margin | 40.6% | 41.7% |
| Operating Cash Flow (Continuing) | $127.0 million | $192.9 million |
| Capital Expenditures | $44.5 million | $28.0 million |
| Total Debt (Short + Long Term) | $152.9 million | $244.4 million |
| Cash and Cash Equivalents | $191.1 million | $502.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 5% to $1,546.4 million, driven by a 6% increase in the Life and Analytical Sciences segment and a 2% increase in Optoelectronics. Acquisitions contributed $21.6 million and favorable foreign exchange rates added $9.8 million.
- Profitability Decline: Net income dropped significantly to $119.6 million from $268.1 million in 2005. The 2005 figure was anomalously high due to a one-time net gain of $186.4 million from the disposition of discontinued operations (Fluid Sciences segment). Excluding discontinued operations, income from continuing operations increased from $66.5 million to $118.3 million.
- Margin Compression: Gross margin decreased 110 basis points to 40.6% due to unfavorable product mix, pricing pressures, and inflation. Cost of sales rose 7%.
- Restructuring: The company recorded a net restructuring reversal of $3.6 million in 2006, compared to charges of $22.1 million in 2005. This was due to the completion of prior plans and lower-than-expected severance costs.
- Debt Reduction: Total debt decreased by approximately $91.5 million as the company repaid its senior subordinated notes in late 2005 and reduced term loans.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D spending to increase in 2007 on both an absolute and percentage-of-sales basis. Capital expenditures for 2007 are projected between $40.0 million and $45.0 million.
- Share Repurchases: The company completed a $190.1 million repurchase of 8.9 million shares in 2006. A new program authorized up to 10.0 million additional shares in November 2006; $57.0 million was spent on repurchases in early 2007.
- Acquisitions: The company completed six acquisitions in 2006 (including Agilix, Spectral Genomics, and Avalon) and two in early 2007 (Evotec and Euroscreen), focusing on drug discovery and genetic screening technologies.
- Risks:
- Intellectual Property: Ongoing litigation with Enzo Biochem and Amersham Biosciences regarding patent infringement. While the company believes it has meritorious defenses, outcomes are uncertain.
- Market Volatility: Quarterly results may fluctuate due to fixed costs, competitive pricing, and economic conditions in key industries (pharmaceuticals, biomedical).
- Foreign Operations: Approximately 62% of sales are international, exposing the company to currency fluctuations and geopolitical risks.
- Intangible Assets: The company holds $1.5 billion in net intangible assets; impairment risks exist if growth targets are not met.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the exclusion of the $186.4 million gain from discontinued operations in 2005 when analyzing year-over-year net income trends.
- Acquisition Integration: Monitor the financial contribution of 2006 and early 2007 acquisitions (Evotec, Euroscreen) to ensure they meet growth expectations.
- Legal Contingencies: Track the status of the Enzo and Amersham patent litigation for potential material liabilities or injunctions.
- Stock-Based Compensation: Note the adoption of SFAS No. 123(R) in 2006, which introduced $9.2 million in stock option expense, affecting comparability with prior years.
- Debt Covenants: Confirm continued compliance with the senior unsecured revolving credit facility covenants (interest coverage and leverage ratios).